Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and BCG in high-risk non-muscle invasive bladder cancer
NCT03799835Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jan 2019
- Primary completion
- Jun 2025
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Unicancer. Started Jan 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03799835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03799835.